Abstract
This is a Phase 3, multicenter, open-label and roll-over study in subjects who are 12 to <24 months of age at initiation of lumacaftor ivacaftor (lum iva) treatment.>24>
This is a Phase 3, multicenter, open-label and roll-over study in subjects who are 12 to <24 months of age at initiation of lumacaftor ivacaftor (lum iva) treatment.>24>